Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IDYA

Ideaya Biosciences Inc

Sep 12 • 12:27PM ET

35.91

Dollar change -0.29
Percentage change -0.80	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF XBI IWO IBB SCHA VTWO VHT LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.18	Insider Own	9.42%	Shs Outstand	84.48M	Perf Week	-3.91%
Market Cap	3.03B	Forward P/E	-	EPS next Y	-2.88	Insider Trans	-2.49%	Shs Float	76.52M	Perf Month	-5.95%
Income	-153.74M	PEG	-	EPS next Q	-0.65	Inst Own	91.70%	Short Float	14.93%	Perf Quarter	-8.88%
Sales	11.96M	P/S	253.65	EPS this Y	-28.85%	Inst Trans	13.15%	Short Ratio	13.30	Perf Half Y	-21.44%
Book/sh	12.24	P/B	2.93	EPS next Y	-14.02%	ROA	-20.48%	Short Interest	11.42M	Perf Year	22.27%
Cash/sh	8.31	P/C	4.32	EPS next 5Y	-	ROE	-21.45%	52W Range	23.41 - 47.74	Perf YTD	0.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.95%	ROI	-16.48%	52W High	-24.77%	Beta	0.85
Dividend TTM	-	Quick Ratio	17.50	Sales past 5Y	14.24%	Gross Margin	64.98%	52W Low	53.40%	ATR (14)	1.49
Dividend Ex-Date	-	Current Ratio	17.50	EPS Y/Y TTM	-50.67%	Oper. Margin	-1600.08%	RSI (14)	37.79	Volatility	4.45% 3.75%
Employees	124	Debt/Eq	0.00	Sales Y/Y TTM	-73.51%	Profit Margin	-1285.34%	Recom	1.08	Target Price	57.46
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-36.36%	Payout	-	Rel Volume	0.11	Prev Close	36.20
Sales Surprise	-100.00%	EPS Surprise	-26.96%	Sales Q/Q	-100.00%	Earnings	Aug 06 BMO	Avg Volume	858.69K	Price	35.91
SMA20	-6.20%	SMA50	-7.99%	SMA200	-9.44%	Trades		Volume	45,691	Change	-0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-24	Initiated	Mizuho	Outperform	$50
Mar-08-24	Initiated	BTIG Research	Buy	$55
Aug-08-23	Initiated	SVB Securities	Outperform	$33
May-24-23	Initiated	Goldman	Buy	$32
Apr-24-23	Upgrade	Stifel	Hold → Buy	$18 → $24
Mar-23-23	Initiated	Berenberg	Buy	$26
Feb-28-23	Initiated	RBC Capital Mkts	Outperform	$25
Dec-28-22	Initiated	CapitalOne	Overweight	$29
Oct-27-22	Initiated	Citigroup	Buy	$26
Aug-15-22	Downgrade	Stifel	Buy → Hold	$16 → $13
Jul-18-22	Resumed	Oppenheimer	Outperform	$25
Mar-10-22	Upgrade	Stifel	Hold → Buy	$27 → $20
Sep-23-21	Initiated	Stifel	Hold	$27
Jun-04-21	Resumed	Robert W. Baird	Outperform	$28
Mar-11-21	Initiated	Guggenheim	Buy	$32
Oct-07-20	Initiated	Wedbush	Outperform	$21
Sep-01-20	Initiated	Northland Capital	Outperform	$28
Jul-13-20	Upgrade	JP Morgan	Neutral → Overweight	$28
Jun-17-20	Reiterated	H.C. Wainwright	Buy	$13 → $22
Apr-06-20	Initiated	H.C. Wainwright	Buy	$13

Show Previous Ratings

Aug-30-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-26-24 06:00AM	IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-23-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-06-24 01:54PM	IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024 (InvestorPlace)
06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
10:01AM	Loading…
Aug-01-24 10:01AM	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-31-24 06:00AM	IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen (PR Newswire)
06:00AM	Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program (Business Wire)
Jul-29-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event (PR Newswire)
Jul-23-24 09:55AM	How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97% (Zacks)
Jul-11-24 04:05PM	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) +6.16%
Jul-09-24 10:26PM	IDEAYA Announces Pricing of Public Offering (PR Newswire)
04:08PM	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
01:49PM	IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data (Zacks)
06:54AM	Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength? (Zacks)
06:52AM	Loading…
06:52AM	IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment (Clinical Trials Arena)
Jul-08-24 04:15PM	Why Ideaya Biosciences Just Made Its Most Bullish Move Since March (Investor's Business Daily) +15.32%
12:57PM	Top Stock Movers Now: Intel, Corning, SolarEdge, and More (Investopedia)
12:08PM	IDEAYA Biosciences Soars on Cancer Drug Study Results (Investopedia)
06:00AM	IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer (PR Newswire)
Jul-05-24 04:05PM	IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024 (PR Newswire)
Jun-28-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-26-24 07:13AM	IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial (Clinical Trials Arena)
Jun-25-24 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer (PR Newswire)
Jun-24-24 06:00AM	IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors (PR Newswire)
Jun-03-24 06:00AM	IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study (PR Newswire) +6.40%
May-31-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-29-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events (PR Newswire)
May-28-24 06:00AM	IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development (PR Newswire)
May-23-24 09:21PM	IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma (PR Newswire) -7.08%
09:21PM	Loading…
09:21PM	/C O R R E C T I O N -- IDEAYA Biosciences, Inc./ (PR Newswire)
May-16-24 05:57PM	Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing (MT Newswires)
May-08-24 08:47AM	Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating (MT Newswires)
May-07-24 01:54PM	IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024 (InvestorPlace)
10:23AM	IDEAYA Biosciences Shares Fall After Q1 Loss (MT Newswires)
07:35AM	IDEAYA Biosciences Inc (IDYA) Reports Q1 2024 Earnings: Financial and Strategic Developments (GuruFocus.com)
06:00AM	IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-01-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event (PR Newswire)
Apr-26-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-24-24 10:05AM	IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study (PR Newswire)
Apr-22-24 06:00AM	IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer (PR Newswire)
Apr-05-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-01-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event (PR Newswire)
Mar-27-24 09:25AM	TipRanks Perfect 10 List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal (TipRanks)
Mar-12-24 06:00AM	IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA (pembrolizumab) in Patients with Endometrial Cancer (PR Newswire)
Mar-04-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events (PR Newswire)
Feb-20-24 06:36AM	IDEAYA Biosciences Q4 Results Misses Estimates (RTT News) -6.62%
06:00AM	IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-13-24 05:37AM	IDEAYA Biosciences Inc CEO Yujiro Hata Sells 99,372 Shares (GuruFocus.com)
Feb-01-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events (PR Newswire)
Jan-26-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-18-24 01:03AM	IDEAYA Biosciences Inc President and CEO Yujiro Hata Sells 75,000 Shares (GuruFocus.com)
Jan-15-24 07:03AM	IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last? (Zacks)
Jan-07-24 09:00AM	IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance (PR Newswire)
Dec-29-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-08-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-05-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event (PR Newswire)
Dec-04-23 06:00AM	IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy and IDE397 Combination in MTAP-Deletion Bladder Cancer (PR Newswire)
Dec-03-23 09:00AM	IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 (PR Newswire)
Nov-14-23 09:55AM	Can IDEAYA Biosciences, Inc. (IDYA) Climb 25.48% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-07-23 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:44AM	IDEAYA Biosciences Inc (IDYA) Reports Q3 2023 Financial Results and Business Update (GuruFocus.com)
06:00AM	IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-01-23 06:00AM	IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference (PR Newswire) +6.33%
Oct-27-23 04:02PM	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) -5.51%
06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-25-23 11:55AM	Why Ideaya Biosciences Stock Is Plummeting Today (Motley Fool)
Oct-24-23 10:15PM	IDEAYA Announces Pricing of Public Offering (PR Newswire)
04:07PM	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
Oct-23-23 06:00AM	IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline (PR Newswire) +5.54%
Oct-18-23 08:33AM	IDEAYA Biosciences, Inc. (IDYA) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-23 06:00AM	IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma (PR Newswire) +7.60%
Oct-16-23 06:00AM	IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma (PR Newswire)
Oct-09-23 06:00AM	IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day (PR Newswire)
Oct-06-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-27-23 06:00AM	IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer (PR Newswire)
Sep-26-23 06:00AM	IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations (PR Newswire)
Sep-15-23 01:03PM	Insider Sell: Chief Legal Officer Jason Throne Sells 1,000 Shares of IDEAYA Biosciences Inc (GuruFocus.com)
Sep-11-23 06:00AM	IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors (PR Newswire)
Sep-05-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events (PR Newswire)
Aug-21-23 06:00AM	IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705) (PR Newswire)
Aug-16-23 06:00AM	IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma (PR Newswire)
Aug-10-23 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-02-23 06:00AM	IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors (PR Newswire)
Aug-01-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event (PR Newswire)
Jul-28-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-30-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-22-23 06:00AM	IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy (PR Newswire)
Jun-12-23 06:00AM	IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types (PR Newswire)
Jun-11-23 09:56AM	Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 223% over the past three years (Simply Wall St.)
May-30-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events (PR Newswire)
May-26-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-22-23 06:00AM	IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors (PR Newswire)
May-16-23 06:00AM	IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma (PR Newswire)
May-09-23 07:25AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +14.62%
06:00AM	IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
May-04-23 10:00AM	Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-02-23 10:02AM	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jason Throne	Former Officer	Aug 26 '24	Proposed Sale	40.22	75,000	3,016,500		Aug 26 05:16 PM
Throne Jason	Chief Legal Officer	Jun 27 '24	Option Exercise	7.77	53,484	415,587	63,484	Jun 27 06:47 PM
WHITE MICHAEL ANTHONY	Chief Scientific Officer	May 29 '24	Option Exercise	12.86	28,500	366,510	28,500	May 31 04:26 PM
WHITE MICHAEL ANTHONY	Chief Scientific Officer	May 29 '24	Sale	36.24	28,500	1,032,884	0	May 31 04:26 PM
Hata Yujiro S	President and CEO	May 15 '24	Option Exercise	4.31	83,856	361,419	761,743	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 14 '24	Option Exercise	4.31	56,711	244,424	734,598	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 16 '24	Option Exercise	4.31	34,433	148,406	712,320	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 15 '24	Sale	42.90	83,856	3,597,756	677,887	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 14 '24	Sale	41.61	56,711	2,359,780	677,887	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 16 '24	Sale	41.81	34,433	1,439,754	677,887	May 16 05:51 PM
Ruiz Briseno Andres	See Remarks	Feb 09 '24	Sale	46.02	2,000	92,045	24,531	Feb 13 04:59 PM
Hata Yujiro S	President and CEO	Feb 08 '24	Option Exercise	4.31	75,815	326,763	753,702	Feb 12 04:27 PM
Hata Yujiro S	President and CEO	Feb 09 '24	Option Exercise	4.31	23,557	101,531	701,444	Feb 12 04:27 PM
Hata Yujiro S	President and CEO	Feb 08 '24	Sale	45.15	75,815	3,422,835	677,887	Feb 12 04:27 PM
Hata Yujiro S	President and CEO	Feb 09 '24	Sale	45.54	23,557	1,072,715	677,887	Feb 12 04:27 PM
Hata Yujiro S	President and CEO	Feb 01 '24	Option Exercise	4.31	628	2,707	678,515	Feb 05 06:05 PM
Hata Yujiro S	President and CEO	Feb 01 '24	Sale	45.00	628	28,260	677,887	Feb 05 06:05 PM
Ruiz Briseno Andres	See Remarks	Jan 22 '24	Sale	42.03	2,000	84,050	26,531	Jan 24 07:12 PM
Ruiz Briseno Andres	See Remarks	Jan 12 '24	Sale	38.01	2,000	76,026	28,531	Jan 17 05:41 PM
Hata Yujiro S	President and CEO	Jan 16 '24	Option Exercise	4.31	62,739	270,405	740,626	Jan 17 05:40 PM
Hata Yujiro S	President and CEO	Jan 12 '24	Option Exercise	4.31	12,261	52,845	690,148	Jan 17 05:40 PM
Hata Yujiro S	President and CEO	Jan 16 '24	Sale	40.17	62,739	2,519,968	677,887	Jan 17 05:40 PM
Hata Yujiro S	President and CEO	Jan 12 '24	Sale	40.04	12,261	490,913	677,887	Jan 17 05:40 PM
Throne Jason	Chief Legal Officer	Dec 15 '23	Option Exercise	13.34	10,000	133,400	10,000	Dec 19 05:37 PM
Throne Jason	Chief Legal Officer	Dec 18 '23	Option Exercise	7.01	10,000	70,100	10,000	Dec 19 05:37 PM
Throne Jason	Chief Legal Officer	Dec 15 '23	Sale	35.04	10,000	350,371	0	Dec 19 05:37 PM
Hata Yujiro S	President and CEO	Dec 15 '23	Option Exercise	4.31	75,000	323,250	752,887	Dec 19 05:34 PM
Hata Yujiro S	President and CEO	Dec 15 '23	Sale	35.03	75,000	2,627,618	677,887	Dec 19 05:34 PM
Ruiz Briseno Andres	See Remarks	Dec 14 '23	Sale	34.00	2,000	68,002	30,531	Dec 18 05:45 PM
Throne Jason	Chief Legal Officer	Nov 03 '23	Option Exercise	12.86	5,163	66,396	5,163	Nov 07 05:47 PM
Throne Jason	Chief Legal Officer	Nov 03 '23	Sale	30.09	5,163	155,360	0	Nov 07 05:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IDYA

Ideaya Biosciences Inc

Upgrade your FINVIZ experience